Photocure $PHO Partners with Asieris on Hexvix in China
Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan
Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries
Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix® in Mainland China and Taiwan.
Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries
Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients, announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix® in Mainland China and Taiwan.
